DC070-547

DC070-547 is a novel, small molecule Ras inhibitor developed by ADT Pharmaceuticals in collaboration with the University of South Alabama Mitchell Cancer Institute. Identified from a library of indene derivatives through phenotypic screening, it is designed to selectively target tumor cells harboring mutant or constitutively active Ras proteins. Preclinical studies demonstrate that DC070-547 potently inhibits the growth of melanoma cell lines, such as SK-MEL-2 (harboring N-Ras mutations) and B16-F10 (harboring upstream PDGFRα mutations), with IC50 values in the low nanomolar range. The compound works by disrupting the Ras signaling pathway, leading to decreased phosphorylation of downstream effectors like c-Raf and MEK. It shows high selectivity (over 100-fold) for cells with activated Ras over those with wild-type Ras levels, and its activity does not appear to be limited to a specific Ras isoform or mutation.